Survival from acute non-lymphocytic leukaemia (ANLL) and chronic myeloid leukaemia (CML) in European children since 1978: a population-based study

We used data supplied by population-based cancer registries, collected and quality controlled using a common protocol, to analyse survival from acute non-lymphocytic leukaemia (ANLL) and chronic myeloid leukaemia (CML) among children in 17 European countries. Variations in survival in relation to ag e, country, histologic subtype and period of diagnosis (1978-1992) were exa mined. These are rare malignancies and survival can be studied reliably onl y by examination of data from a very large population (in this case EUROCAR E). 5 years after diagnosis, overall survival was 44% (95% CI 33-55) for CM L and 37% (95% CI 32-43) for ANLL. For both types of leukaemia, survival wa s slightly better for girls and worse in children under 5 years of age. Con sistent with clinical literature, the ANLL subtypes with poorer prognosis w ere monocytic, megakaryocytic and erythroleukaemia. For ANLL, 5-year surviv al was better in Finland, the UK, The Netherlands and Germany (greater than or equal to 40%); for CML, 5-year survival was highest in Italy, although the 95% CI were wide. The risk of death from ANLL and CML fell by 7% per ye ar and 5% per year, respectively, after adjustment for age, gender and coun try. Since these rare childhood malignancies were virtually untreatable unt il 1970, these are very welcome trends. (C) 2001 Elsevier Science Ltd. All rights reserved.